Format

Send to

Choose Destination
See comment in PubMed Commons below
Diabetes Care. 2008 Feb;31(2):363-5. Epub 2007 Oct 24.

Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome.

Author information

  • 1Leeds Institute of Genetics, Health & Therapeutics, LIGHT Laboratories, University of Leeds, Leeds, UK.

Abstract

OBJECTIVE:

We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS).

RESEARCH DESIGN AND METHODS:

We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes.

RESULTS:

Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50-1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use.

CONCLUSIONS:

Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.

PMID:
17959865
DOI:
10.2337/dc07-1745
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center